Is Alterity Therapeutics Stock a Good Investment?
Alterity Therapeutics Investment Advice | ATHE |
- Examine Alterity Therapeutics' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Alterity Therapeutics' leadership team and their track record. Good management can help Alterity Therapeutics navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Alterity Therapeutics' business and its evolving consumer preferences.
- Compare Alterity Therapeutics' performance and market position to its competitors. Analyze how Alterity Therapeutics is positioned in terms of product offerings, innovation, and market share.
- Check if Alterity Therapeutics pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Alterity Therapeutics' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Alterity Therapeutics stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Alterity Therapeutics is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Slightly risky | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Almost neglects market trends | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Poor | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Alterity Therapeutics Stock
Researching Alterity Therapeutics' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). The company has price-to-book (P/B) ratio of 1.04. Some equities with similar Price to Book (P/B) outperform the market in the long run. Alterity Therapeutics recorded a loss per share of 1.88. The entity had not issued any dividends in recent years. The firm had 1:10 split on the 9th of January 2023.
To determine if Alterity Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Alterity Therapeutics' research are outlined below:
| Alterity Therapeutics generated a negative expected return over the last 90 days | |
| Alterity Therapeutics has some characteristics of a very speculative penny stock | |
| Alterity Therapeutics has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 2.68 M. Net Loss for the year was (19.12 M) with profit before overhead, payroll, taxes, and interest of 3.63 M. | |
| Alterity Therapeutics currently holds about 34.81 M in cash with (8.41 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.87. | |
| Alterity Therapeutics has a poor financial position based on the latest SEC disclosures | |
| Latest headline from thelincolnianonline.com: Alterity Therapeutics Limited Short Interest Down 41.9 percent in October |
Alterity Therapeutics Quarterly Cost Of Revenue |
|
Earnings surprises can significantly impact Alterity Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Alterity Therapeutics' investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2021-08-30 | 2021-06-30 | -0.1718 | -0.1334 | 0.0384 | 22 | ||
2019-02-28 | 2018-12-31 | -0.27 | -0.0036 | 0.2664 | 98 | ||
2018-08-31 | 2018-06-30 | -0.28 | -0.0036 | 0.2764 | 98 | ||
2019-08-30 | 2019-06-30 | -0.36 | -0.0022 | 0.3578 | 99 | ||
2020-02-27 | 2019-12-31 | -0.4 | -0.0026 | 0.3974 | 99 | ||
2017-02-24 | 2016-12-31 | -0.54 | -0.01 | 0.53 | 98 |
Know Alterity Therapeutics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Alterity Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Alterity Therapeutics backward and forwards among themselves. Alterity Therapeutics' institutional investor refers to the entity that pools money to purchase Alterity Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Ubs Group Ag | 2024-06-30 | 2.0 | Xtx Topco Ltd | 2024-06-30 | 0.0 | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 96.8 K | Hb Wealth Management, Llc | 2024-09-30 | 23.8 K | Susquehanna International Group, Llp | 2024-06-30 | 23.3 K | Twin Lakes Capital Management, Llc | 2024-06-30 | 5.9 K | Providence Capital Advisors, Llc | 2024-06-30 | 200 | Advisor Group Holdings, Inc. | 2024-06-30 | 81.0 | Ronald Blue Trust, Inc. | 2024-09-30 | 40.0 | Sugarloaf Wealth Management, Llc | 2024-09-30 | 33.0 | Corecap Advisors, Llc | 2024-06-30 | 21.0 |
Alterity Therapeutics' market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 10.24 M.Market Cap |
|
Alterity Therapeutics' profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.99) | (1.04) | |
| Return On Capital Employed | (1.42) | (1.49) | |
| Return On Assets | (0.99) | (1.04) | |
| Return On Equity | (1.39) | (1.32) |
Determining Alterity Therapeutics' profitability involves analyzing its financial statements and using various financial metrics to determine if Alterity Therapeutics is a good buy. For example, gross profit margin measures Alterity Therapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Alterity Therapeutics' profitability and make more informed investment decisions.
Please note, the presentation of Alterity Therapeutics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Alterity Therapeutics' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Alterity Therapeutics' management manipulating its earnings.
Evaluate Alterity Therapeutics' management efficiency
Alterity Therapeutics has return on total asset (ROA) of (0.5266) % which means that it has lost $0.5266 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.0447) %, meaning that it created substantial loss on money invested by shareholders. Alterity Therapeutics' management efficiency ratios could be used to measure how well Alterity Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of November 23, 2024, Return On Tangible Assets is expected to decline to -1.04. In addition to that, Return On Capital Employed is expected to decline to -1.49. At present, Alterity Therapeutics' Other Current Assets are projected to increase significantly based on the last few years of reporting. The current year's Fixed Asset Turnover is expected to grow to 22.58, whereas Non Current Assets Total are forecasted to decline to about 177.5 K.| Last Reported | Projected for Next Year | ||
| Enterprise Value Over EBITDA | (0.29) | (0.31) | |
| Price Book Value Ratio | 1.32 | 1.39 | |
| Enterprise Value Multiple | (0.29) | (0.31) | |
| Price Fair Value | 1.32 | 1.39 | |
| Enterprise Value | 5.8 M | 5.5 M |
Examining the leadership quality of Alterity Therapeutics offers valuable insights into its operational efficiency and financial health. This analysis assists investors in making informed decisions regarding the stock.
Beta 0.684 |
Basic technical analysis of Alterity Stock
As of the 23rd of November, Alterity Therapeutics shows the Mean Deviation of 2.94, risk adjusted performance of (0.05), and Standard Deviation of 3.96. Alterity Therapeutics technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Please confirm Alterity Therapeutics standard deviation, as well as the relationship between the treynor ratio and potential upside to decide if Alterity Therapeutics is priced correctly, providing market reflects its regular price of 1.07 per share. Given that Alterity Therapeutics is a hitting penny stock territory we recommend to closely look at its jensen alpha.Alterity Therapeutics' Outstanding Corporate Bonds
Alterity Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Alterity Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Alterity bonds can be classified according to their maturity, which is the date when Alterity Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| Altice France 8125 Corp BondUS02156LAA98 | View | |
| ALTICE FRANCE S Corp BondUS02156LAE11 | View | |
| Altice France 55 Corp BondUS02156LAC54 | View | |
| US02156LAH42 Corp BondUS02156LAH42 | View | |
| US02156LAF85 Corp BondUS02156LAF85 | View | |
| Altice Europe 5 Corp BondUS02154CAF05 | View |
Understand Alterity Therapeutics' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Alterity Therapeutics' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.05) | |||
| Market Risk Adjusted Performance | 1.0 | |||
| Mean Deviation | 2.94 | |||
| Coefficient Of Variation | (1,442) | |||
| Standard Deviation | 3.96 | |||
| Variance | 15.69 | |||
| Information Ratio | (0.10) | |||
| Jensen Alpha | (0.25) | |||
| Total Risk Alpha | (0.91) | |||
| Treynor Ratio | 0.9944 | |||
| Maximum Drawdown | 23.32 | |||
| Value At Risk | (7.14) | |||
| Potential Upside | 5.34 | |||
| Skewness | 0.42 | |||
| Kurtosis | 1.92 |
| Risk Adjusted Performance | (0.05) | |||
| Market Risk Adjusted Performance | 1.0 | |||
| Mean Deviation | 2.94 | |||
| Coefficient Of Variation | (1,442) | |||
| Standard Deviation | 3.96 | |||
| Variance | 15.69 | |||
| Information Ratio | (0.10) | |||
| Jensen Alpha | (0.25) | |||
| Total Risk Alpha | (0.91) | |||
| Treynor Ratio | 0.9944 | |||
| Maximum Drawdown | 23.32 | |||
| Value At Risk | (7.14) | |||
| Potential Upside | 5.34 | |||
| Skewness | 0.42 | |||
| Kurtosis | 1.92 |
Consider Alterity Therapeutics' intraday indicators
Alterity Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Alterity Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Alterity Therapeutics time-series forecasting models is one of many Alterity Therapeutics' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Alterity Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
Alterity Stock media impact
Far too much social signal, news, headlines, and media speculation about Alterity Therapeutics that are available to investors today. That information is available publicly through Alterity media outlets and privately through word of mouth or via Alterity internal channels. However, regardless of the origin, that massive amount of Alterity data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Alterity Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Alterity Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Alterity Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Alterity Therapeutics alpha.
Alterity Therapeutics Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Alterity Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Alterity Therapeutics Corporate Management
| Robert Cherny | Head Research | Profile | |
| BBus CA | Company Sec | Profile | |
| BSc BSc | CoFounder Chairman | Profile | |
| Kathryn Andrews | Chief Officer | Profile | |
| Steven Targum | Chief Advisor | Profile | |
| CPA BCom | Chief Officer | Profile | |
| Steven MD | Chief Advisor | Profile |
Already Invested in Alterity Therapeutics?
The danger of trading Alterity Therapeutics is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Alterity Therapeutics is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Alterity Therapeutics. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Alterity Therapeutics is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Alterity Therapeutics is a strong investment it is important to analyze Alterity Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Alterity Therapeutics' future performance. For an informed investment choice regarding Alterity Stock, refer to the following important reports: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Alterity Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate. For information on how to trade Alterity Stock refer to our How to Trade Alterity Stock guide.You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Alterity Therapeutics. If investors know Alterity will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Alterity Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.88) | Revenue Per Share 0.6 | Quarterly Revenue Growth 0.384 | Return On Assets (0.53) | Return On Equity (1.04) |
The market value of Alterity Therapeutics is measured differently than its book value, which is the value of Alterity that is recorded on the company's balance sheet. Investors also form their own opinion of Alterity Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Alterity Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Alterity Therapeutics' market value can be influenced by many factors that don't directly affect Alterity Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between Alterity Therapeutics' value and its price, as these two are different measures arrived at by various means. Investors typically determine if Alterity Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Alterity Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.